KK
CLYM

Kotler Kevin’s Climb Bio CLYM Stock Holding History

Kotler Kevin’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.6M Buy
+400,000
New +$961K 0.37% 21

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Kotler Kevin's CLYM Position: Q4 2025 in Review

Kotler Kevin opened a new position in Climb Bio (CLYM) in Q4 2025: 400,000 shares worth $1.6M. The stake represents 0.37% of the portfolio and ranks #21 among its holdings.

65 funds tracked by Wall St. Rank hold CLYM as of Q4 2025.

  • Kotler Kevin held 400,000 shares of Climb Bio worth $1.6M as of Q4 2025.
  • Climb Bio was a new Kotler Kevin position in Q4 2025.
  • Climb Bio made up 0.37% of Kotler Kevin's portfolio in Q4 2025, its #21 holding.
  • 65 funds tracked by Wall St. Rank held Climb Bio as of Q4 2025.

Based on Kotler Kevin's 13F filing for Q4 2025, filed 17 Feb 2026.